Trials / Recruiting
RecruitingNCT06928818
Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Prospective Observational Study of Trastuzumab Emtansine Immediately After Trastuzumab Deruxtecan in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Korea
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea
Conditions
Timeline
- Start date
- 2025-02-26
- Primary completion
- 2028-09-30
- Completion
- 2029-09-30
- First posted
- 2025-04-15
- Last updated
- 2025-04-17
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06928818. Inclusion in this directory is not an endorsement.